Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument

Summary Background While current medications used to treat patients with chronic hepatitis C virus (HCV) effectively produce sustained viral response (SVR), postponement of therapy is oftentimes attributed to patient perceptions of unfavourable outcomes. However, an instrument to assess patient perc...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2013-03, Vol.37 (5), p.573-582
Main Authors: Szeinbach, S. L., Baran, R. W., Dietz, B., Gazzouola Rocca, L., Littlefield, D., Yawn, B. P.
Format: Article
Language:English
Subjects:
Adult
Age
Aged
Biological and medical sciences
Cognitive ability
Development
Digestive system
Drug Therapy - psychology
Factor analysis
Female
Focus Groups
Gastroenterology. Liver. Pancreas. Abdomen
Hepacivirus
Hepatitis C virus
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - psychology
Human viral diseases
Humans
Infectious diseases
Male
Manganese
Medical sciences
Middle Aged
Patient Satisfaction
Perception
Pharmacology. Drug treatments
Side effects
Social aspects
Viral diseases
Viral hepatitis
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background While current medications used to treat patients with chronic hepatitis C virus (HCV) effectively produce sustained viral response (SVR), postponement of therapy is oftentimes attributed to patient perceptions of unfavourable outcomes. However, an instrument to assess patient perceptions of therapy (i.e. treatment satisfaction) has not been developed. Aim To describe the development and validation the chronic Hepatitis C Virus Treatment Satisfaction (HCVTSat) instrument. Methods Focus groups, expert review and cognitive debriefing were used to develop a draft 37‐item instrument (scale: 1 = not important at all; 5 = extremely important). The preliminary instrument was administered to a pre‐test sample of 145 patients through Mayo Clinic, Rochester, MN. A refined HCVTSat was administered to a main sample of 333 participants with a chronic HCV diagnosis through Harris Interactive. Results The HCVTSat was completed by 333 participants with an average age of 51 (s.d. = 12.1) years, 55% male, current or previous HCV treatment experience, and a diagnosis of HCV for approximately 12 (s.d. = 8.9) years. Twelve items for the 3 dimensions, Treatment Experience (TE), Side Effects (SE) and Social Aspects (SA), were internally consistent (Cronbach's α range: 0.70–0.90), responsive and valid. Confirmatory factor analysis (goodness‐of‐fit indexes: χ2 = 20.9, df = 23, P = 0.59; CFI = 1.00, GFI = 0.99, TFI = 1.00, RMSEA = 0.001) revealed a better fit with 9 items. All path coefficients were significant (P 
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.12202